##plugins.themes.bootstrap3.article.main##

As we know, the Philadelphia chromosome (Ph) is a highly specific marker for chronic myeloid leukemia (CML). This hematological disease is characterised by the formation of the BCR/ABL1 fusion gene, usually with typical translocation pattern including 9q34 and 22q11. In this paper we describe a 55 years old female patient with typical clinical and haematological signs of CML and a chromosome 9 differing from that which normally participates in translocation t(9;22). The karyotype of this Ph positive patient is characterised by pericentric inv(9)(p13q34) of the der(9)t(9;22)(q34;q11). Reverse transcriptase-polymerase chain reaction revealed a e14a2 type of BCR/ABL1 fusion transcript. As a consequence of this unusual translocation, FISH also found the separation of the ABL1/BCR1 fusion gene on chromosome 9. On reviewing the literature, to date only 10 Ph-positive leukemia patients have been noticed to have pericentric inversion inv(9)(p22q34)der(9)t(9;22)(q34;q11). No one case has been described with pericentric inversion inv(9)(p13q34) of the der(9)t(9;22)(q34;q11). This indicate that pericentric inv(9)(p13q34) of the der(9)t(9;22)(q34;q11) is a novel, rare, chromosomal abnormality in Ph-positive CML.

Downloads

Download data is not yet available.

References

  1. Melo JV, Goldman JM. Myeloproliferative disorders. Springer. 2007;182-2015.
    DOI  |   Google Scholar
  2. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa banding. Nature. 1973; 243: 290–293.
    DOI  |   Google Scholar
  3. Melo JV, Gordon DE, Cross NCP, Goldman JM. The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia. Blood. 1998; 81(1): 158-165.
    DOI  |   Google Scholar
  4. Chomczynski P, Sacchi N. Single-step method of DNA/RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem.1987; 162(1): 156-9.
    DOI  |   Google Scholar
  5. Cross NCP, White HE, Colomer D, Ehrencrona H, Foroni L, Gottard E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015; 29(5): 999-1003.
    DOI  |   Google Scholar
  6. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4): 966-984.
    DOI  |   Google Scholar
  7. Pan J, Xue Y, Qiu H, Chen S, Zhang J, Wu Y, et al. A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia. Cancer Genet Cytogenet. 2010; 203(2): 333-40.
    DOI  |   Google Scholar
  8. Fan Y, Ding SS, Pan JL, Xue YQ, Hu ZH. Clinical and laboratory investigation of pericentric inv(9)(p22q34) with the der(9)t(9;22)(q34;q11) in Ph-positive leukemia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2013; 30(2): 157-60. Chinese.
     Google Scholar
  9. Jain PP, Parihar M, Ahmed R, Abraham A, Vishwabandya A, George B, et al. Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis. Indian J Pathol Microbiol. 2012; 55(3): 347-51.
    DOI  |   Google Scholar
  10. Hughes T, Saglio G, Kantarijan HM, Guilhot F, Niederwieser D, Rosti G. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9): 1353–1360.
    DOI  |   Google Scholar
  11. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperlay JF, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia. Blood. 2013; 122: 872–84.
    DOI  |   Google Scholar